Correlation Between Stoke Therapeutics and Blueprint Medicines
Can any of the company-specific risk be diversified away by investing in both Stoke Therapeutics and Blueprint Medicines at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Stoke Therapeutics and Blueprint Medicines into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Stoke Therapeutics and Blueprint Medicines Corp, you can compare the effects of market volatilities on Stoke Therapeutics and Blueprint Medicines and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Stoke Therapeutics with a short position of Blueprint Medicines. Check out your portfolio center. Please also check ongoing floating volatility patterns of Stoke Therapeutics and Blueprint Medicines.
Diversification Opportunities for Stoke Therapeutics and Blueprint Medicines
0.12 | Correlation Coefficient |
Average diversification
The 3 months correlation between Stoke and Blueprint is 0.12. Overlapping area represents the amount of risk that can be diversified away by holding Stoke Therapeutics and Blueprint Medicines Corp in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Blueprint Medicines Corp and Stoke Therapeutics is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Stoke Therapeutics are associated (or correlated) with Blueprint Medicines. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Blueprint Medicines Corp has no effect on the direction of Stoke Therapeutics i.e., Stoke Therapeutics and Blueprint Medicines go up and down completely randomly.
Pair Corralation between Stoke Therapeutics and Blueprint Medicines
Given the investment horizon of 90 days Stoke Therapeutics is expected to under-perform the Blueprint Medicines. In addition to that, Stoke Therapeutics is 1.12 times more volatile than Blueprint Medicines Corp. It trades about -0.04 of its total potential returns per unit of risk. Blueprint Medicines Corp is currently generating about 0.2 per unit of volatility. If you would invest 8,277 in Blueprint Medicines Corp on August 28, 2024 and sell it today you would earn a total of 1,110 from holding Blueprint Medicines Corp or generate 13.41% return on investment over 90 days.
| Time Period | 3 Months [change] |
| Direction | Moves Together |
| Strength | Insignificant |
| Accuracy | 100.0% |
| Values | Daily Returns |
Stoke Therapeutics vs. Blueprint Medicines Corp
Performance |
| Timeline |
| Stoke Therapeutics |
| Blueprint Medicines Corp |
Stoke Therapeutics and Blueprint Medicines Volatility Contrast
Predicted Return Density |
| Returns |
Pair Trading with Stoke Therapeutics and Blueprint Medicines
The main advantage of trading using opposite Stoke Therapeutics and Blueprint Medicines positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Stoke Therapeutics position performs unexpectedly, Blueprint Medicines can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Blueprint Medicines will offset losses from the drop in Blueprint Medicines' long position.| Stoke Therapeutics vs. Adaptimmune Therapeutics Plc | Stoke Therapeutics vs. Black Diamond Therapeutics | Stoke Therapeutics vs. Relay Therapeutics | Stoke Therapeutics vs. Pliant Therapeutics |
| Blueprint Medicines vs. Eliem Therapeutics | Blueprint Medicines vs. HCW Biologics | Blueprint Medicines vs. Scpharmaceuticals | Blueprint Medicines vs. Milestone Pharmaceuticals |
Check out your portfolio center.Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Bond Analysis module to evaluate and analyze corporate bonds as a potential investment for your portfolios..
Other Complementary Tools
| Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
| Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
| Fundamental Analysis View fundamental data based on most recent published financial statements | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| Equity Valuation Check real value of public entities based on technical and fundamental data |